18-Methoxycoronaridine

A potential new treatment for obesity in rats?

Olha Taraschenko, Heather Y. Rubbinaccio, Isabelle M. Maisonneuve, Stanley D. Glick

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Rationale: Excessive eating often leads to obesity. Although a variety of neurotransmitters and brain regions are involved in modulating food intake, a role of accumbal dopamine is thought to be critical for several aspects of this behavior. Since 18-methoxycoronaridine (18-MC), a selective antagonist of α3β4 nicotinic receptors, was previously shown to alter dopamine release in the nucleus accumbens in response to chronic injections of cocaine and morphine, this drug could be a promising therapy for abnormal eating behavior. Objectives: Assess the effect of 18-MC on the consumption of sucrose (15%) vs. water in a self-administration paradigm and on the intake of freely available palatable fluids (i.e., 5% sucrose, 0.1% saccharin, and 0.6% saline solutions) as well as on water intake. Determine whether repeated administration of 18-MC (20 mg/kg i.p.) affects weight gain, food intake, and fat deposition in rats drinking 30% sucrose solution. Results: Acute administration of 18-MC (10-40 mg/kg i.p.) reduced operant responding for sucrose and decreased ad libitum ingestion of sucrose, saccharin, and saline. The highest dose of 18-MC also reduced consumption of water when palatable fluids were not available. In rats having unlimited access to sucrose (30%), chronic treatment with 18-MC (20 mg/kg i.p.) prevented sucrose-induced increases in body weight, decreased fat deposition, and reduced consumption of sucrose while not altering food intake. Conclusions: These data suggest that antagonism of α3β4 nicotinic receptors may be involved in the regulation of intake of palatable substances regardless of its caloric value and may participate in maintaining obesity.

Original languageEnglish (US)
Pages (from-to)339-350
Number of pages12
JournalPsychopharmacology
Volume201
Issue number3
DOIs
StatePublished - Dec 1 2008

Fingerprint

Sucrose
Obesity
Eating
Drinking
Saccharin
Nicotinic Receptors
Therapeutics
Dopamine
Fats
Self Administration
18-methoxycoronaridine
Nucleus Accumbens
Feeding Behavior
Cocaine
Sodium Chloride
Morphine
Weight Gain
Neurotransmitter Agents
Body Weight
Injections

Keywords

  • Feeding behavior
  • Nicotinic receptors
  • Obesity
  • Palatable fluids

ASJC Scopus subject areas

  • Pharmacology

Cite this

18-Methoxycoronaridine : A potential new treatment for obesity in rats? / Taraschenko, Olha; Rubbinaccio, Heather Y.; Maisonneuve, Isabelle M.; Glick, Stanley D.

In: Psychopharmacology, Vol. 201, No. 3, 01.12.2008, p. 339-350.

Research output: Contribution to journalArticle

Taraschenko, Olha ; Rubbinaccio, Heather Y. ; Maisonneuve, Isabelle M. ; Glick, Stanley D. / 18-Methoxycoronaridine : A potential new treatment for obesity in rats?. In: Psychopharmacology. 2008 ; Vol. 201, No. 3. pp. 339-350.
@article{985d970cb464480491f730b4455dad89,
title = "18-Methoxycoronaridine: A potential new treatment for obesity in rats?",
abstract = "Rationale: Excessive eating often leads to obesity. Although a variety of neurotransmitters and brain regions are involved in modulating food intake, a role of accumbal dopamine is thought to be critical for several aspects of this behavior. Since 18-methoxycoronaridine (18-MC), a selective antagonist of α3β4 nicotinic receptors, was previously shown to alter dopamine release in the nucleus accumbens in response to chronic injections of cocaine and morphine, this drug could be a promising therapy for abnormal eating behavior. Objectives: Assess the effect of 18-MC on the consumption of sucrose (15{\%}) vs. water in a self-administration paradigm and on the intake of freely available palatable fluids (i.e., 5{\%} sucrose, 0.1{\%} saccharin, and 0.6{\%} saline solutions) as well as on water intake. Determine whether repeated administration of 18-MC (20 mg/kg i.p.) affects weight gain, food intake, and fat deposition in rats drinking 30{\%} sucrose solution. Results: Acute administration of 18-MC (10-40 mg/kg i.p.) reduced operant responding for sucrose and decreased ad libitum ingestion of sucrose, saccharin, and saline. The highest dose of 18-MC also reduced consumption of water when palatable fluids were not available. In rats having unlimited access to sucrose (30{\%}), chronic treatment with 18-MC (20 mg/kg i.p.) prevented sucrose-induced increases in body weight, decreased fat deposition, and reduced consumption of sucrose while not altering food intake. Conclusions: These data suggest that antagonism of α3β4 nicotinic receptors may be involved in the regulation of intake of palatable substances regardless of its caloric value and may participate in maintaining obesity.",
keywords = "Feeding behavior, Nicotinic receptors, Obesity, Palatable fluids",
author = "Olha Taraschenko and Rubbinaccio, {Heather Y.} and Maisonneuve, {Isabelle M.} and Glick, {Stanley D.}",
year = "2008",
month = "12",
day = "1",
doi = "10.1007/s00213-008-1290-9",
language = "English (US)",
volume = "201",
pages = "339--350",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - 18-Methoxycoronaridine

T2 - A potential new treatment for obesity in rats?

AU - Taraschenko, Olha

AU - Rubbinaccio, Heather Y.

AU - Maisonneuve, Isabelle M.

AU - Glick, Stanley D.

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Rationale: Excessive eating often leads to obesity. Although a variety of neurotransmitters and brain regions are involved in modulating food intake, a role of accumbal dopamine is thought to be critical for several aspects of this behavior. Since 18-methoxycoronaridine (18-MC), a selective antagonist of α3β4 nicotinic receptors, was previously shown to alter dopamine release in the nucleus accumbens in response to chronic injections of cocaine and morphine, this drug could be a promising therapy for abnormal eating behavior. Objectives: Assess the effect of 18-MC on the consumption of sucrose (15%) vs. water in a self-administration paradigm and on the intake of freely available palatable fluids (i.e., 5% sucrose, 0.1% saccharin, and 0.6% saline solutions) as well as on water intake. Determine whether repeated administration of 18-MC (20 mg/kg i.p.) affects weight gain, food intake, and fat deposition in rats drinking 30% sucrose solution. Results: Acute administration of 18-MC (10-40 mg/kg i.p.) reduced operant responding for sucrose and decreased ad libitum ingestion of sucrose, saccharin, and saline. The highest dose of 18-MC also reduced consumption of water when palatable fluids were not available. In rats having unlimited access to sucrose (30%), chronic treatment with 18-MC (20 mg/kg i.p.) prevented sucrose-induced increases in body weight, decreased fat deposition, and reduced consumption of sucrose while not altering food intake. Conclusions: These data suggest that antagonism of α3β4 nicotinic receptors may be involved in the regulation of intake of palatable substances regardless of its caloric value and may participate in maintaining obesity.

AB - Rationale: Excessive eating often leads to obesity. Although a variety of neurotransmitters and brain regions are involved in modulating food intake, a role of accumbal dopamine is thought to be critical for several aspects of this behavior. Since 18-methoxycoronaridine (18-MC), a selective antagonist of α3β4 nicotinic receptors, was previously shown to alter dopamine release in the nucleus accumbens in response to chronic injections of cocaine and morphine, this drug could be a promising therapy for abnormal eating behavior. Objectives: Assess the effect of 18-MC on the consumption of sucrose (15%) vs. water in a self-administration paradigm and on the intake of freely available palatable fluids (i.e., 5% sucrose, 0.1% saccharin, and 0.6% saline solutions) as well as on water intake. Determine whether repeated administration of 18-MC (20 mg/kg i.p.) affects weight gain, food intake, and fat deposition in rats drinking 30% sucrose solution. Results: Acute administration of 18-MC (10-40 mg/kg i.p.) reduced operant responding for sucrose and decreased ad libitum ingestion of sucrose, saccharin, and saline. The highest dose of 18-MC also reduced consumption of water when palatable fluids were not available. In rats having unlimited access to sucrose (30%), chronic treatment with 18-MC (20 mg/kg i.p.) prevented sucrose-induced increases in body weight, decreased fat deposition, and reduced consumption of sucrose while not altering food intake. Conclusions: These data suggest that antagonism of α3β4 nicotinic receptors may be involved in the regulation of intake of palatable substances regardless of its caloric value and may participate in maintaining obesity.

KW - Feeding behavior

KW - Nicotinic receptors

KW - Obesity

KW - Palatable fluids

UR - http://www.scopus.com/inward/record.url?scp=56549084703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56549084703&partnerID=8YFLogxK

U2 - 10.1007/s00213-008-1290-9

DO - 10.1007/s00213-008-1290-9

M3 - Article

VL - 201

SP - 339

EP - 350

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 3

ER -